Gina Mauro | Authors


Oral Paclitaxel, Encequidar Continues to Improve OS in Metastatic Breast Cancer

December 09, 2020

Treatment with oral paclitaxel, compared with the intravenous formulation, in combination with encequidar led to an estimated 26.5% reduction in the risk of death in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.